Compass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 2026 July 29, 2026 Compass Management will host a conference call at 8:00 am ET (1:00 pm UK)
Smurfit Westrock Reports Second Quarter 2026 Results July 29, 2026 Smurfit Westrock plc (NYSE: SW) today announced the financial results for the second quarter ended June 30, 2026. Key Points: Net Sales of $8,031 million Net Income of $88 million, with a Net Income Margin of 1.1% Adjusted EBITDA1 of $1,140 million, with an Adjusted EBITDA Margin1 of 14.2% Net Cash Provided by Operating Activities [...]
Bureau Veritas: Delivering on Our Commitments With Higher Sequential Organic Growth in Q2 and Continuous Margin Improvements July 29, 2026 Bureau Veritas (BOURSE:BVI): H1 2026 key figures1 › Revenue of EUR 3,258.4 million in H1 2026, up 2.1% year-on-year and up 5.0% organically (with a sequential improvement in Q2 2026 at 5.5% organic growth), › Adjusted operating profit of EUR 506.5 million, up 3.1% versus EUR 491.5 million in H1 2025, representing an adjusted operating [...]
Luxfer Enters Into Agreement to Be Acquired for $17.37 Per Share in All-Cash Transaction; Reports Second Quarter Results July 28, 2026 On July 26, 2026, Luxfer Holdings PLC entered into a definitive agreement to be acquired by affiliates of Wynnchurch Capital, L.P. (“Wynnchurch”) in an all-cash transaction. Under the terms of the agreement, unanimously approved by the directors in attendance at a meeting of Luxfer's Board of Directors, Luxfer shareholders will receive $17.37 per ordinary share in cash. Second Quarter 2026 Highlights* GAAP Net Sales of $95.7 million from $106.6 million, Adjusted Sales 1 declined 3.7% GAAP Net Income was $4.8 million, or $0.18 per diluted share, compared to $2.6 million and $0.10 per diluted share Adjusted EBITDA1 decreased to $13.4 million, down 4.3%, and Adjusted Diluted EPS1 decreased 3.3% to $0.29 Strong Margin Performance, with adjusted gross margin up 130bps to 25.2% and Adjusted EBITDA1 margin of 14.3% GAAP Measures now include the Superform business, previously reported as a discontinued operation. * Comparative information is relative to prior-year second quarter. 1 Note: Adjusted results exclude Superform and Graphic Arts businesses.
Logitech Announces Q1 Fiscal Year 2027 Results July 28, 2026 Strong First Quarter Marks Tenth Consecutive Quarter of Growth
Alkermes plc Reports Second Quarter 2026 Financial Results July 28, 2026 Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended June 30, 2026. To view the detailed second quarter 2026 earnings press release and presentation, please visit the company’s investor relations website at https://investor.alkermes.com. Alkermes will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) today, to discuss [...]
Algoma Central Corporation to Issue Second Quarter Financial Results on August 7, 2026 July 24, 2026 Algoma Central Corporation (TSX: ALC) today announced it will report its financial results for the three and six months ended June 30, 2026 before market open on August 7, 2026. The Company’s second quarter earnings release and full financial results will be available on the Company’s website and on SEDAR. Algoma Central Corporation is a [...]
Almirall H1 2026 Results July 24, 2026 Almirall delivers solid H1 2026 results growing Net Sales by 7.5% and EBITDA by 23.7%, driven by its strong European Dermatology business – reiterating guidance aligned with long-term growth trajectory Net Sales increased by 7.5% YoY to €602.7 MM, while EBITDA grew by 23.7% to €150.7 MM, reflecting strong commercial and operational execution. The European Dermatology business continues to drive growth, increasing 18.1% YoY to €341.9 MM, supported by strong performance of its key growth drivers and favourable underlying market growth. Continued solid performance of the biologics portfolio, with Ilumetri® delivering 10.5% increase to €125.2 MM and Ebglyss® growing 88.2% to €84.5 MM in Net Sales, supported by sustained growth in recent launch markets. The broader dermatology portfolio delivers positive performance, including Wynzora® (19.3%, total of €20.4 MM) and Klisyri® (13.9%, total of €15.6 MM). Almirall advances its innovation strategy through progress across its R&D pipeline, including four ongoing PoC/Phase II studies and two additional PoC studies planned to be initiated by end of 2026, targeting five dermatological diseases. The first readouts are expected towards the end of 2026. Almirall signs a strategic research collaboration and licensing agreement with Certest Biotec to discover and develop novel treatments for rare dermatologic diseases and recurrent cutaneous conditions. Reiterated guidance for the full year 2026: 9-12% growth and € 270MM to € 290MM EBITDA.
Allegion (NYSE: ALLE) Reports Q2-2026 Financial Results July 23, 2026 Low-Double Digit Revenue Growth, High-Teens EPS Growth; Raising Full-Year 2026 Outlook Quarterly Financial Highlights (All comparisons are year-over-year, unless otherwise noted) Net earnings per share (EPS) of $2.15, up 16.2% compared with $1.85; Adjusted EPS of $2.40, up 17.6% compared with $2.04 Revenues of $1,151.5 million, up 12.7% on a reported basis and up 6.9% on an organic basis Operating margin of 22.1%, compared with 21.5%; Adjusted operating margin of 24.2%, compared with 23.7%
Luxfer Announces Date of Second Quarter 2026 Earnings Conference Call July 22, 2026 Luxfer Holdings PLC (NYSE: LXFR) (“Luxfer” or the “Company”), a global industrial company innovating niche applications in materials engineering, today announced the details for its second quarter 2026 earnings conference call. Date and time: Wednesday July 29, 2026, at 8:30 a.m. Eastern Time Luxfer participants: Andy Butcher Chief Executive Officer Steve Webster Chief Financial [...]